Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

First-line treatment selection with organoids of an EGFRm + TP53m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up

1 Jul 2020

Abstract excerpt

chemotherapy with or

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Diagnosis and Treatment
Share to Lung Cancer Research Studies
Share to Lung Cancer Treatments and Mutations

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 32802455
DOI: 10.21037/jtd-20-1882

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First-line treatment selection with organoids of an EGFRm + TP53m stage IA1 patient with early metastatic recurrence after radical surgery and follow-upPMID 32802455Read ↗

Organoids: An intermediate modeling platform in precision oncologySemantic proximity Read ↗

The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific SocietiesSemantic proximity Read ↗

Towards functional precision oncology with human organoidsSemantic proximity Read ↗

Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2–Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therapy With Description of Sequencing and Organoid CorrelatesSemantic proximity Read ↗

Targeting cancer drug resistance utilizing organoid technologySemantic proximity Read ↗

Moving beyond cisplatin resistance: mechanisms, challenges, and prospects for overcoming recurrence in clinical cancer therapySemantic proximity Read ↗

INTERESTing biomarker to select IDEAL patients for epidermal growth factor receptor tyrosine kinase inhibitors: yes, for EGFR mutation analysis, others, I PASS.Semantic proximity Read ↗

Closing in on cancer heterogeneity with organoidsSemantic proximity Read ↗

Organoid Models Established from Primary Tumors and Patient-Derived Xenograft Tumors Reflect Platinum Sensitivity of Ovarian Cancer PatientsSemantic proximity Read ↗

Establishment and Long-Term Expansion of Small Cell Lung Cancer Patient-Derived Tumor OrganoidsSemantic proximity Read ↗

Comprehensive tumor profiling-guided therapy in rare or refractory solid cancer: A feasibility study in daily clinical practice.Semantic proximity Read ↗

Developing patient-derived organoids to predict PARP inhibitor response and explore resistance overcoming strategies in ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.